Erik Domines
Net worth: 174 $ as of 2024-04-29
Profile
Erik Domines worked as the General Counsel at Recipharm AB from 2014 to 2018 and at Xbrane Biopharma AB from 2021 to 2023.
He completed his undergraduate degree at the University of Stockholm.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
XBRANE BIOPHARMA AB
0.00% | 2022-12-30 | 8,821 ( 0.00% ) | 174 $ | 2024-04-29 |
Former positions of Erik Domines
| Companies | Position | End |
|---|---|---|
| XBRANE BIOPHARMA AB | General Counsel | 2023-06-30 |
| RECIPHARM AB (PUBL) | General Counsel | 2018-12-30 |
Training of Erik Domines
| University of Stockholm | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| XBRANE BIOPHARMA AB | Health Technology |
| Private companies | 1 |
|---|---|
Recipharm AB
 Recipharm AB BiotechnologyHealth Technology Recipharm AB engages in the manufacture of pharmaceuticals and contract development services for pharmaceutical companies. It operates through the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment produces products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Erik Domines
